Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma Inc. (SILO) is a biopharmaceutical innovator developing novel therapies that combine traditional treatments with psychedelic research for conditions including PTSD and chronic pain. This dedicated news hub provides investors and researchers with essential updates on the company's clinical progress, strategic partnerships, and therapeutic advancements.
Access centralized, reliable information about Silo Pharma's pipeline developments, including its intranasal SPC-15 formulation for stress disorders and SP-26 implant technology for pain management. The page aggregates official press releases, research milestones, and financial disclosures while maintaining strict compliance with financial reporting standards.
Key updates cover clinical trial phases, intellectual property developments, university research collaborations, and regulatory filings. All content is verified through primary sources to ensure accuracy and timeliness for stakeholders tracking the company's progress in psychedelic-assisted therapeutics and advanced drug delivery systems.
Bookmark this page for streamlined access to Silo Pharma's latest announcements. For comprehensive tracking of the company's innovative approach to CNS disorder treatments, consider subscribing to Stock Titan's news alerts.
Silo Pharma (OTC QB: SILO) announced the extension of its exclusive option agreement with the University of Maryland to explore joint-homing peptides for treating rheumatoid arthritis and other autoimmune diseases. This technology aims to enhance therapeutic delivery to diseased joints, improving treatment efficacy while minimizing systemic toxicity. CEO Eric Weisblum highlighted the potential of these peptides as a revolutionary drug delivery platform, emphasizing the need for innovative therapeutics for rare diseases.
Silo Pharma, Inc. (OTCQB: SILO) announced the engagement of Donohoe Advisory Associates for consulting services related to a potential NASDAQ up-listing. This strategic move aims to enhance visibility and attract a broader investor base. CEO Eric Weisblum emphasized that listing on NASDAQ could increase liquidity for shareholders, although approval and compliance with listing requirements are not guaranteed. Silo Pharma is focused on developing psychedelic therapies for conditions like depression and PTSD, seeking transformative solutions for patients.
Silo Pharma, Inc. (OTCQB: SILO) announced the issuance of U.S. Patent No. 11,174,287 for a novel homing peptide aimed at enhancing therapeutic targeting in the central nervous system (CNS). This advancement could improve pharmacological treatments, allowing for lower dosages and reduced side effects. CEO Eric Weisblum expressed optimism about expanding their intellectual property (IP) portfolio and the potential for this technology to transform treatment options for CNS disorders. The patent emphasizes the importance of targeting neuroinflammation in CNS tissues.
Silo Pharma, Inc. (OTCQB: SILO) announced a significant milestone as its joint venture partner, Zylo Therapeutics, received its first ketamine shipment, marking the initiation of ketamine loading into the Z-Pod® transdermal technology. CEO Eric Weisblum emphasized that this advancement is pivotal for therapeutic applications of ketamine and could potentially enhance the delivery of psilocybin. Silo Pharma focuses on merging traditional therapies with psychedelic research to address mental health issues such as depression and PTSD.
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma (OTCQB: SILO), a biopharmaceutical company focused on psychedelics for therapeutic use, reported its third quarter 2021 financial results and business updates. Key highlights include a research agreement with Columbia University for Alzheimer’s therapeutic development, a patent allowance from the U.S. Patent Office for CNS homing peptides, and DEA approval for a joint venture to deliver ketamine. The company has approximately $11 million in working capital and aims to uplist to the Nasdaq, enhancing long-term shareholder value.
Silo Pharma (OTCQB: SILO) has entered a sponsored research agreement with Columbia University to explore options for licensing Alzheimer’s therapeutic assets. Under the leadership of Dr. Christine Ann Denny, the initiative focuses on understanding molecular mechanisms linked to Alzheimer’s disease and memory retrieval. With 5.8 million Americans affected by Alzheimer’s, this collaboration aims to develop innovative treatments using psychedelic compounds, potentially providing significant improvements in cognitive health.
Silo Pharma (OTCQB: SILO) has entered a research agreement with Columbia University focused on developing treatments for Alzheimer’s disease. This partnership involves Dr. Christine Ann Denny, who studies the molecular mechanisms of memory and learning. Silo has the option to license certain assets related to this research, which aims to explore the therapeutic potential of ketamine for improving memory retrieval and addressing cognitive decline. The agreement represents a significant step in Silo's efforts to provide innovative solutions for patients suffering from Alzheimer’s and related conditions.
Silo Pharma (OTCQB: SILO) announced that its joint venture partner, Zylo Therapeutics, received DEA approval to develop Z-pod technology with Ketamine. CEO Eric Weisblum expressed optimism about creating a transdermal Ketamine therapeutic using this patented technology, which may also deliver Psilocybin in a controlled manner. This development aims to provide innovative solutions for patients suffering from depression, PTSD, Parkinson’s, and other neurological disorders. Updates on this partnership are anticipated as milestones are achieved.
Silo Pharma, Inc. (OTCQB: SILO) announced the filing of three Patent Cooperation Treaty (PCT) applications aimed at protecting its intellectual property related to the central nervous system delivery of unique anti-inflammatory therapeutics combined with psilocybin. This step is part of the company’s commitment to research and development in the biopharmaceutical space, specifically targeting conditions like depression and PTSD. The applications focus on the therapeutic potential of psychedelics and anti-inflammatory drugs, expanding possible treatment options for various neurological disorders.
On August 11, 2021, Silo Pharma (OTCQB:SILO) announced that its partner, ZYLO Therapeutics, successfully completed its first inspection with the SC Board of Pharmacy. This milestone enables progress with the Department of Health and Environmental Control towards developing a transdermal Ketamine therapeutic leveraging patented Z-Pod® technology. CEO Eric Weisblum emphasized the significance of this step, highlighting the potential for controlled, time-released delivery of Ketamine or Psilocybin.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
